External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home APLAR 2025
Roche and Genentech at

APLAR 2025

September 03 - September 07
Fukuoka, Japan
aplarcongress.com
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon
05:30 AM
Duration 145mins Fukuoka, Japan
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obinutuzumab in Patients with Systemic Lupus Erythematosus
Edward M. Vital, Zahir Amoura, Stella Botha, Maria A. D'Agostino, Sunil Kumar, Fedra I. Palazuelos, Grzegorz Rozumek, Adolfina E. Zuta Santillán, Viviane A. Souza, Biruh Workeneh, Justine Maller, Oliver Meier, Jay P. Garg, Richard A. Furie
Rheumatology | Systemic Lupus Erythematosus

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
02:10 AM
Duration 10mins Fukuoka Covention Center (FCC)
Kidney-Related Outcomes With Obinutuzumab in Patients With Active Lupus Nephritis: A Pre-Specified Exploratory Analysis of the REGENCY Study
Brad H. Rovin, William F. Pendergraft III, Liz Lightstone, Eric Daugas, Richard A. Furie, Theodore A. Omachi, Imran Hassan, Elsa Martins, Thomas Schindler, Jay P. Garg, Luis F. Quintana, Piotr Leszczyński, Ana Malvar
Rheumatology - Nephrology | Lupus Nephritis

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.